Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
Purpose: Primary central nervous system lymphoma (PCNSL) is a rare type of extra-nodal non-Hodgkin lymphoma, but the prognostic value of blood parameters indicating systemic inflammation and nutritional status remains unknown. We aim to explore the prognostic role of blood parameters in PCNSL.Method...
Main Authors: | Qian Luo, Chunli Yang, Chunxi Fu, Wanchun Wu, Yi Wei, Liqun Zou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.639644/full |
Similar Items
-
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
by: Yuting Gao, et al.
Published: (2021-08-01) -
Improvement of outcomes of an escalated high‐dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study
by: Li Q, et al.
Published: (2021-08-01) -
CD markers polymorphisms as prognostic biomarkers in hematological malignancies
by: Saeid Shahrabi, et al.
Published: (2020-07-01) -
Relapsed Primary Central Nervous System Lymphoma: Current Advances
by: Kaiyan Tao, et al.
Published: (2021-04-01) -
Treatment of primary central nervous system lymphomas
by: I. V. Cherkashina, et al.
Published: (2021-06-01)